Clinical trials: Hepatitis C, completed
Chronic Hepatitis C
Safety and PK Study of MP-424 to Treat Chronic Hepatitis C
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
- Trial name
- NCT00591214
- Testing
- MP-424 (Telaprevir)
- Where
- Japan
- Volunteers
- 10 people
- Sponsor
- Tanabe Pharma Corporation
Hepatitis C Virus (HCV)
Safety and Efficacy Study of Peginterferon Lambda-1a vs. Peginterferon Alfa-2a, Plus Ribavirin in Subjects With Genotype 1 Hepatitis C
The purpose of this study is to determine if 48 weeks of therapy with Peginterferon Lambda plus Ribavirin is effective and safe for a treatment of chronic hepatitis C (CHC) compared to therapy with Peginterferon alfa-2a plus…
- Trial name
- BASIS (NCT01754974)
- Testing
- Peginterferon Lambda-1a, Ribavirin, Peginterferon alfa-2a
- Where
- 16 sites in Czechia, Mexico and 1 more
- Volunteers
- 40 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
Hepatitis C Antiviral Resistance in African-Americans
This study is designed to test the hypothesis that African-Americans respond less well to combination pegylated interferon and ribavirin therapy than Caucasian-Americans who have chronic hepatitis C genotype 1 and who were not…
- Trial name
- NCT00038974
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 8 sites in United States
- Volunteers
- 401 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis C
Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C
Background: Hepatitis C is a liver disease caused by the hepatitis C virus. It is the most common cause of serious liver disease in the United States. Many people have few if any symptoms.
- Trial name
- NCT02118012
- Testing
- Chlorcyclizine HCl, Ribavirin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hepatitis C Virus, HIV
Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection
This study will evaluate the antiviral efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) administered for 12 weeks in hepatitis C virus (HCV) treatment-naive and…
- Trial name
- NCT02073656
- Testing
- LDV/SOF, RBV
- Where
- 41 sites in United States, Canada and 2 more
- Volunteers
- 335 people
- Sponsor
- Gilead Sciences
Hepatitis C, Viruses
TMC435-TiDP16-C107: This Study Measures the (Possible) Influence of TMC435 on the Activity of a Selected Set of Drug-degrading Proteins by Measuring the Blood Levels of Drugs That Have Been Taken Together With TMC435 and That Are Known to be Specifically Degraded by These Drug-degrading Proteins.
The purpose of this study is to determine whether TMC435 influences the activity of certain drug-degrading proteins in the human body.
- Trial name
- NCT00866853
- Testing
- TMC435
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Hepatitis C
Safety Study of INX-08189, Pharmacokinetic and Pharmacodynamic With Ribavirin and Food Effect Study, in Chronically-infected Genotype 1 Hepatitis C Virus, Treatment-naïve Subjects
This study is to determine the safety and Pharmacokinetics (PK) and Pharmacodynamics (PD) of INH-08189 dosed once a day (QD), two times a day (BID) or adjunctively with Ribavirin and a study of the food effect in…
- Trial name
- INH-189-006 (NCT01445795)
- Testing
- 200 mg INX-08189 Fasted, 100 mg INX-08189 QD, 100 mg INX-08189 with low-fat meal
- Where
- 2 sites in United States, Puerto Rico
- Volunteers
- 50 people
- Sponsor
- Bristol-Myers Squibb
Chronic HCV Infection
Phase 2 Study of Yimitasvir Phosphate Capsules
The safety, tolerability and antiviral activity of DAG181/SOF in treatment-naive and treatment-experienced patients with chronic hepatitis C virus (HCV) genotype 1 infection
- Trial name
- NCT03458481
- Testing
- SOF, DAG181
- Where
- 17 sites in China
- Volunteers
- 129 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Hepatitis C, Chronic
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS Plus COPEGUS Compared With PEGASYS Plus COPEGUS in Patients With Chronic Hepatitis C Genotype 1 Infection.
This 7 arm study will determine the optimal treatment combination, based on efficacy and safety. Patients with chronic hepatitis C (CHC), genotype 1, will be randomized to one of 7 treatment groups.
- Trial name
- NCT00517439
- Testing
- Copegus, Pegasys, RO4588161
- Where
- 63 sites in United States, Australia and 7 more
- Volunteers
- 516 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study to Evaluate the Safety and Efficacy of Celgosivir in Patients With Chronic Hepatitis C Genotype 1 Infection
The objective of the study is to evaluate the safety and efficacy of celgosivir for 12 weeks in patients with chronic hepatitis C genotype 1 infection.
- Trial name
- NCT00157534
- Testing
- Celgosivir
- Volunteers
- 43 people
- Sponsor
- BioWest Therapeutics Inc
Hepatitis C, Chronic, Hematologic Malignancy
Pharmacokinetics of Ledipasvir/Sofosbuvir in Hepatitis C Virus-Infected Children With Hematological Malignancy
This is a prospective, controlled, open-label, pharmacokinetic study. This study aims at studying the PK of ledipasvir, sofosbuvir, and GS-331007 metabolite in HCV infected children with hematological malignancy.
- Trial name
- NCT03903185
- Testing
- Ledipasvir / Sofosbuvir Oral Product
- Where
- 2 sites in Egypt
- Volunteers
- 24 people
- Sponsor
- Ain Shams University
Hepatitis C, Opiate Dependence
A Video-Based HCV Curriculum for Drug Users
The investigators hypothesize that a well-designed hepatitis C (HCV)video education curriculum for high-risk drug users will show measurable benefits in improving HCV testing, hepatitis A and B vaccinations, and HCV knowledge…
- Trial name
- NCT00241917
- Testing
- Hepatitis C educational video, Video
- Where
- 3 sites in United States
- Volunteers
- 450 people
- Sponsor
- Organization to Achieve Solutions in Substance Abuse (OASIS)
Hepatitis C
Study Comparing Daclatasvir (BMS-790052) With Telaprevir Combined With Peginterferon Alfa-2a and Ribavirin in Patients With Chronic Hepatitis C Virus Infection
The purpose of this study is to compare the effectiveness of BMS-790052 (Daclatasvir) and Telaprevir when given in combination with Peginterferon alfa-2a and Ribavirin in genotype 1b patients
- Trial name
- COMMAND-3 (NCT01492426)
- Testing
- Daclatasvir, Telaprevir, Peginterferon alfa-2a
- Where
- 91 sites in United States, Argentina and 14 more
- Volunteers
- 605 people
- Sponsor
- Bristol-Myers Squibb
HIV Infection, Liver Failure
Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients
This phase I/II, multi-center study is designed to determine the pharmacokinetic profile of Raltegravir in patients with end stage liver disease and to assess drug-drug interaction when Raltegravir is combined with…
- Conditions
- HIV Infection, Liver Failure, Evidence of Liver Transplantation
- Trial name
- LIVERAL (NCT01022476)
- Testing
- Raltegravir potassium
- Where
- France
- Volunteers
- 14 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HCV, HIV
KP-Led Same Day HCV Test and Treat Study
This is a Hybrid design to primarily assess effectiveness, and to secondarily observe and collect data on the implementation of the service.
- Trial name
- 479/65 (NCT05479760)
- Testing
- KP-Led HCV test and treat service
- Where
- 4 sites in Thailand
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Institute of HIV Research and Innovation Foundation, Thailand
Hepatitis C Virus Infection
Absolute Bioavailability of BMS-791325
The purpose of this study is to determine the absolute bioavailability of 150 mg oral dose of BMS-791325 relative to 100 µg IV infusion of [13C]-BMS-791325.
- Trial name
- NCT02112110
- Testing
- BMS-791325, [13C]-BMS-791325
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Fluvastatin, Rosuvastatin Added to Pegylated Interferon and Ribavirin
Hypothesis: addition of fluvastatin will increase the cure rate of standard anti-HCV therapy. Summary: This trial is limited to veterans in Oklahoma who qualify for care with the Veterans Administration.
- Trial name
- NCT00487318
- Testing
- standard of care, fluvastatin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bader, Ted, M.D.
Beta Thalassemia Major
Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C
Thalassemics can develop liver fibrosis because of iron overload and hepatitis C infection. The latter is the main risk factor for liver fibrosis in transfusion dependent thalassemics.
- Trial name
- NCT02744560
- Testing
- spirulina
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Tanta University
Hepatitis C
Cross-Over Study to Assess the Cardiovascular Effects of GSK2336805
This is a single-center, randomized, two part, double-blind, crossover study in healthy adult subjects to assess the effect of a single dose of GSK2336805 150mg on cardiac function comparing with placebo using echocardiography as…
- Trial name
- NCT01424540
- Testing
- GSK2336805 150mg
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C
Antiviral & Antifibrotic Liver Therapy in HCV + Drinkers and Non-Drinkers
The primary aim of this investigation is to evaluate the effect of a combined antiviral, antifibrotic and antioxidant treatment on the progression of liver disease in patients with hepatitis C who either abstain from alcohol or…
- Trial name
- NCT00211848
- Testing
- Polyenylphosphatidylcholine (PPC), Pegylated Interferon, Ribavirin
- Where
- United States
- Volunteers
- 207 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.